International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS)

Artificial Intelligence for Computational Theranostics: Integrating Molecular Imaging, Nanomedicine, and Precision Oncology

Dr.Nishita Roy[1],Dr.Arun Mathew[2],Dr.Megha Sharma[3],Mrs.Aditi Rao[4],Dr.Salman Ahmed[5],Dr.Jyoti Verma[6]

[1]Professor.Department of Medical Oncology, Chettinad Hospital & Research Institute, Chennai, India.Nishitaroy81@gmail.com
[2]Associate Professor,Department of Pharmacology, Chettinad Hospital & Research Institute, Chennai, India.Arunmathew90@gmail.com
[3]Assistant Professor,Department of Biochemistry, Chettinad Hospital & Research Institute, Chennai, India.Meghasharma24@gmail.com
[4]Assistant Professor,Department of Clinical Pharmacy, Chettinad Hospital & Research Institute, Chennai, India.Aditirao137@gmail.com
[5]Professor,Department of Radiology, Chettinad Hospital & Research Institute, Chennai, India.Salman.ahmed69@gmail.com
[6]Associate Professor,Department of Microbiology, Chettinad Hospital & Research Institute, Chennai, India.Jyotiverma46@gmail.com

ABSTRACT

Cancer remains one of the leading causes of morbidity and mortality worldwide despite remarkable advances in molecular diagnostics, targeted therapeutics, immunotherapy, and precision medicine. The convergence of molecular imaging, nanomedicine, and artificial intelligence (AI) has given rise to computational theranostics, an emerging paradigm that combines diagnosis, therapy, therapeutic monitoring, and personalized decision-making within unified computational frameworks. Molecular imaging modalities—including positron emission tomography (PET), single-photon emission computed tomography (SPECT), computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and optical imaging—provide non-invasive visualization of tumor biology, while nanomedicine enables targeted drug delivery, molecular imaging enhancement, and precision therapeutics. Artificial intelligence, through machine learning, deep learning, multimodal learning, transformer architectures, graph neural networks, generative AI, and foundation models, integrates these diverse biomedical datasets with genomics, digital pathology, laboratory biomarkers, and longitudinal clinical information to optimize diagnosis, treatment selection, therapeutic response prediction, and personalized cancer care. AI-driven computational theranostics has demonstrated remarkable potential in radiomics, radiopharmaceutical development, nanoparticle engineering, immunotherapy prediction, adaptive treatment planning, digital twins, and clinical decision support. Despite substantial progress, important challenges remain regarding multimodal data integration, explainability, computational scalability, regulatory validation, cybersecurity, and ethical implementation. This review provides a comprehensive overview of computational theranostics, highlighting current innovations, clinical applications, implementation challenges, and future perspectives for precision oncology.[1]

Keywords: Computational theranostics, Artificial intelligence, Molecular imaging, Nanomedicine, Precision oncology, Radiomics, Machine learning, Precision medicine, Digital twins, Clinical decision support.

Article Info
Received: 05 December 2025, received in revised form: 15 December 2025, accepted: 20 December 2025, available online: 30 December 2025; Volume: 1; Issue: 5; Pages: 98-106.

Citation: Roy N.,2025.Artificial Intelligence for Computational Theranostics: Integrating Molecular Imaging, Nanomedicine, and Precision Oncology. *International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS) 2(1): 98-106.*

DOI:

1. Introduction

Cancer is a biologically heterogeneous disease characterized by genomic instability, molecular diversity, immune dysregulation, metabolic reprogramming, and dynamic interactions within the tumor microenvironment. Although advances in targeted therapies and precision medicine have improved patient outcomes, individualized treatment remains challenging because patients with similar pathological diagnoses frequently demonstrate markedly different therapeutic responses and long-term prognoses.[2]

Theranostics represents a paradigm in which diagnostic imaging and targeted therapy are integrated into a unified clinical strategy. Molecular imaging identifies disease location, biological activity, and therapeutic targets, whereas targeted therapeutics selectively deliver treatment according to patient-specific molecular characteristics. The rapid evolution of nanotechnology and computational medicine has further expanded theranostic capabilities by enabling highly personalized diagnosis and therapy.[3]

Artificial intelligence has emerged as the computational engine driving modern theranostics through automated analysis of multimodal biomedical information generated from molecular imaging, nanomedicine, genomics, digital pathology, laboratory investigations, wearable technologies, and electronic health records. AI enables integration of these heterogeneous datasets into comprehensive computational frameworks supporting precision oncology.[4]

The convergence of molecular imaging, nanomedicine, and artificial intelligence is creating a new era of computational theranostics in which diagnosis, treatment planning, therapeutic monitoring, and adaptive clinical decision-making become increasingly personalized and data driven.[5]

2. Evolution of Computational Theranostics

Traditional oncology relied upon separate diagnostic and therapeutic pathways in which imaging primarily identified anatomical abnormalities while treatment decisions were based upon histopathology and clinical staging. Although effective, these approaches often lacked individualized biological characterization and real-time therapeutic adaptation.[6]

The emergence of molecular imaging transformed oncology by enabling visualization of tumor metabolism, receptor expression, angiogenesis, cellular proliferation, and therapeutic targets using PET, SPECT, MRI, and hybrid imaging technologies. Simultaneously, nanomedicine introduced nanoparticles capable of targeted drug delivery, image enhancement, controlled drug release, and molecular diagnostics.[7]

Artificial intelligence further revolutionized theranostics by enabling automated interpretation of imaging biomarkers, nanoparticle behavior, molecular pathways, treatment response, and longitudinal clinical outcomes. Deep learning, multimodal foundation models, graph neural networks, and generative AI now facilitate comprehensive computational integration across diagnostic and therapeutic domains.

Modern computational theranostics therefore extends beyond conventional imaging or drug delivery by creating intelligent precision oncology ecosystems that continuously adapt therapeutic strategies according to evolving patient biology.[8]

3. Principles of Computational Theranostics

Computational theranostics integrates molecular imaging, targeted therapeutics, nanotechnology, artificial intelligence, and longitudinal clinical information into unified computational systems that support individualized cancer management.[9]

The diagnostic component acquires multimodal information from PET, SPECT, CT, MRI, ultrasound, optical imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, and electronic health records. Therapeutic components include radiopharmaceuticals, targeted therapies, nanoparticle-based drug delivery systems, immunotherapy, radiation therapy, and molecularly guided interventions.

Artificial intelligence harmonizes these heterogeneous datasets through multimodal learning while generating comprehensive patient-specific computational representations capable of predicting disease progression, therapeutic response, toxicity, recurrence, and survival.

Continuous incorporation of longitudinal clinical information allows computational theranostic systems to evolve throughout diagnosis, treatment, follow-up, and survivorship, enabling adaptive precision medicine rather than static clinical decision-making.[10]

4. Artificial Intelligence Technologies Driving Computational Theranostics

Artificial intelligence provides the computational intelligence that enables integration of complex biomedical information across diagnostic and therapeutic domains. Machine learning algorithms identify nonlinear relationships among imaging biomarkers, molecular characteristics, nanomedicine parameters, laboratory investigations, and patient outcomes, facilitating prediction of diagnosis, recurrence, therapeutic response, and survival.[11]

Deep learning substantially expands computational capabilities through automated extraction of hierarchical features from molecular imaging, digital pathology, and physiological data. Transformer architectures efficiently process multimodal biomedical information, whereas graph neural networks model biological interactions involving genes, proteins, signaling pathways, immune networks, and pharmacological targets.

Foundation models further strengthen computational scalability through generalized biomedical representation learning that can subsequently be adapted across multiple oncology applications with limited task-specific retraining.

Together, these complementary technologies support increasingly comprehensive computational theranostic systems capable of individualized clinical reasoning.[12]

5. Molecular Imaging in Precision Oncology

Molecular imaging provides non-invasive visualization of biological processes occurring within tumors, enabling assessment of metabolic activity, receptor expression, angiogenesis, cellular proliferation, hypoxia, immune responses, and therapeutic targets. Positron emission tomography, single-photon emission computed tomography, magnetic resonance imaging, computed tomography, ultrasound, and optical imaging each contribute complementary information regarding tumor biology.[13]

Artificial intelligence enhances molecular imaging by automatically detecting tumors, segmenting lesions, quantifying imaging biomarkers, predicting molecular characteristics, and monitoring therapeutic response through longitudinal image analysis.

Radiomics further expands these capabilities by extracting hundreds of quantitative imaging biomarkers describing tumor morphology, texture, vascularity, metabolism, and spatial heterogeneity. AI integrates these biomarkers with molecular biology and clinical information to improve diagnosis, prognostic prediction, and therapeutic planning.[14]

6. Nanomedicine and Targeted Drug Delivery

Nanomedicine has become an essential component of computational theranostics through development of nanoscale drug delivery systems capable of selectively targeting malignant tissues while minimizing systemic toxicity. Liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, lipid nanoparticles, and exosome-based carriers provide controlled drug delivery, molecular imaging enhancement, and targeted therapeutic interventions.[15]

Artificial intelligence supports nanoparticle design by optimizing particle size, surface chemistry, drug loading, pharmacokinetics, biodistribution, targeting efficiency, and controlled drug release. Machine learning further predicts nanoparticle interactions with biological systems while facilitating development of personalized nanomedicine strategies.

Integration of nanotechnology with molecular imaging enables simultaneous diagnosis and treatment within unified theranostic platforms capable of continuously monitoring therapeutic efficacy.[16]

7. Radiopharmaceuticals and AI-Assisted Theranostics

Radiopharmaceuticals have become increasingly important within precision oncology by enabling both molecular imaging and targeted radionuclide therapy. Diagnostic isotopes identify biological targets, whereas therapeutic isotopes selectively deliver radiation to malignant tissues expressing specific molecular markers.[17]

Artificial intelligence supports radiopharmaceutical development through automated target identification, molecular docking prediction, dosimetry optimization, toxicity estimation, and patient selection. Deep learning also assists interpretation of PET and SPECT imaging while predicting therapeutic response based on quantitative molecular imaging biomarkers.

These computational approaches strengthen personalized radionuclide therapy by integrating imaging phenotypes, molecular biology, laboratory investigations, and clinical outcomes into individualized treatment strategies.[18]

8. Computational Radiomics and Imaging Biomarkers

Radiomics represents one of the principal computational components of theranostics by converting routine medical images into high-dimensional quantitative datasets suitable for artificial intelligence analysis. Imaging biomarkers extracted from CT, MRI, PET, and hybrid imaging describe tumor heterogeneity, vascularity, metabolism, morphology, texture, and spatial organization.[19]

Artificial intelligence integrates radiomic features with digital pathology, genomics, transcriptomics, proteomics, laboratory biomarkers, and longitudinal clinical information to generate comprehensive patient-specific computational representations.

These multimodal imaging biomarkers improve diagnosis, molecular subtype classification, treatment selection, therapeutic monitoring, recurrence prediction, and long-term clinical decision-making while supporting increasingly individualized computational theranostics.[20]

9. Radiopathomics in Precision Cancer Diagnosis

One of the most significant clinical applications of AI-driven radiopathomics is precision cancer diagnosis through integrated interpretation of radiological imaging and digital pathology. Unlike conventional diagnostic workflows in which radiologists and pathologists analyze data independently, radiopathomics combines macroscopic imaging phenotypes with microscopic tissue architecture to generate comprehensive patient-specific diagnostic models.[22]

Artificial intelligence integrates radiomic biomarkers, histomorphological characteristics, molecular alterations, laboratory biomarkers, and clinical documentation to improve tumor detection, disease classification, molecular subtype identification, staging, and individualized risk assessment. Deep learning algorithms identify subtle biological relationships between imaging findings and histopathological features that may not be apparent through conventional visual interpretation.These integrated diagnostic models improve diagnostic consistency, reduce interobserver variability, and facilitate multidisciplinary collaboration while supporting earlier and more accurate cancer diagnosis.

10. Personalized Therapeutics and Treatment Optimization

Radiopathomics plays an increasingly important role in personalized cancer therapy by integrating imaging, pathology, genomics, and longitudinal clinical information into unified computational frameworks capable of predicting individualized therapeutic response.[23]

Machine learning algorithms estimate treatment sensitivity, recurrence probability, progression-free survival, overall survival, treatment-related toxicity, and mechanisms of therapeutic resistance across chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations.

Artificial intelligence continuously incorporates updated imaging studies, pathological findings, laboratory investigations, and treatment responses, allowing therapeutic recommendations to evolve throughout the patient's disease course. This adaptive computational approach supports increasingly personalized precision oncology while minimizing unnecessary toxicity and ineffective treatment.

11. Radiopathomics in Immunotherapy and Tumor Microenvironment Analysis

The tumor microenvironment strongly influences cancer progression and responsiveness to immunotherapy. AI-driven radiopathomics integrates radiological imaging with computational pathology to characterize immune-cell infiltration, stromal architecture, angiogenesis, immune checkpoint expression, vascular remodeling, and spatial cellular organization.[24]

Deep learning algorithms analyze radiomic biomarkers together with digital pathology features to estimate responsiveness to immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, bispecific antibodies, and adoptive cellular therapies.

By combining macroscopic anatomical information with microscopic immune architecture, radiopathomics provides a comprehensive assessment of the biological environment that determines immunotherapy outcomes while supporting individualized treatment strategies.

12. Drug Discovery and Clinical Decision Support

Artificial intelligence-powered radiopathomics is accelerating oncology drug discovery through integration of imaging phenotypes, histopathological biomarkers, molecular biology, systems pharmacology, and clinical outcomes. Machine learning identifies therapeutic targets, predicts drug-target interactions, estimates toxicity profiles, and models mechanisms of treatment resistance using comprehensive multimodal biological information.[25]

Within routine clinical practice, radiopathomics contributes to intelligent clinical decision-support systems that integrate imaging studies, pathology reports, genomic sequencing, laboratory investigations, medication history, treatment response, and electronic health records into interactive patient-specific dashboards.

These systems provide evidence-based recommendations regarding diagnosis, therapeutic planning, toxicity prediction, recurrence surveillance, and survivorship care while maintaining physician oversight and multidisciplinary collaboration.

13. Explainable Artificial Intelligence and Clinical Translation

Because radiopathomics integrates multiple highly complex biomedical modalities, explainability becomes essential for successful clinical implementation. Explainable artificial intelligence (XAI) enables clinicians to understand how computational models combine radiological imaging and histopathological features through saliency maps, Grad-CAM visualization, SHAP (Shapley Additive Explanations), feature attribution analysis, attention mechanisms, and counterfactual reasoning.[26]

These transparent computational explanations allow radiologists and pathologists to verify whether artificial intelligence focuses on biologically meaningful structures while facilitating multidisciplinary interpretation of AI-generated recommendations.

Despite remarkable progress, important implementation challenges remain regarding multimodal data harmonization, computational scalability, interoperability, algorithmic bias, cybersecurity, patient privacy, regulatory approval, and prospective clinical validation across diverse healthcare environments.

14. Emerging Innovations and Future Perspectives

Rapid advances in computational oncology continue to expand the capabilities of AI-driven radiopathomics. Multimodal foundation models trained on large biomedical datasets are expected to improve cross-modal reasoning while requiring less task-specific retraining. Digital twins integrating radiological imaging, pathology, genomics, laboratory biomarkers, wearable technologies, and longitudinal clinical information may enable continuous simulation of disease progression and therapeutic response.[27]

Additional innovations including spatial multi-omics, liquid biopsy, federated learning, single-cell sequencing, quantum computing, agentic artificial intelligence, cloud-native healthcare infrastructure, and generative AI are expected to further strengthen radiopathomic ecosystems while improving scalability, robustness, and clinical accessibility.

Future intelligent oncology platforms may seamlessly integrate radiology, pathology, molecular biology, and real-time clinical information into continuously learning computational systems capable of supporting adaptive precision medicine throughout the cancer care continuum.

15. Discussion

AI-driven radiopathomics represents one of the most significant advances in computational oncology by integrating complementary biological information obtained from radiological imaging and digital pathology into unified computational representations. Unlike conventional diagnostic approaches that analyze imaging and pathology independently, radiopathomics combines macroscopic anatomical characteristics with microscopic tissue architecture to provide a more comprehensive understanding of tumor biology.[28]

Applications spanning cancer diagnosis, molecular characterization, prognostic prediction, personalized therapeutics, immunotherapy, drug discovery, digital twins, and clinical decision support demonstrate the remarkable translational potential of this multidisciplinary computational framework.

Nevertheless, widespread implementation requires standardized multimodal data integration, explainable artificial intelligence, robust interoperability, secure computational infrastructure, prospective multicenter validation, and close collaboration among radiologists, pathologists, oncologists, computer scientists, biomedical engineers, and regulatory agencies.

16. Conclusion

AI-driven radiopathomics is redefining precision oncology by integrating radiological imaging, digital pathology, molecular biology, laboratory biomarkers, and longitudinal clinical information into unified computational frameworks capable of supporting comprehensive personalized cancer care.[29]

Through advances in multimodal learning, transformer architectures, graph neural networks, foundation models, digital twins, federated learning, and generative artificial intelligence, radiopathomics is expected to substantially improve diagnostic accuracy, therapeutic optimization, biomarker discovery, disease monitoring, and clinical decision-making across multiple cancer types.

Although important scientific, technical, ethical, and regulatory challenges remain, continued interdisciplinary collaboration will accelerate responsible clinical translation of radiopathomics, ultimately improving patient outcomes and advancing the future of precision medicine by bridging radiology and pathology into a single intelligent computational ecosystem.[30]

17. References

1.Synthia,F. et al.(2020)‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.

2.Huang,S.C. et al.(2021)‘Self-supervised Learning for Medical Image Classification: A Systematic Review’, IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.

3.Moor,M. et al.(2023)‘Foundation Models for Generalist Medical Artificial, Nature, 616(7956), pp. 259-265.

4.Wei,L. et al.(2023)‘Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration’, British Journal of Radiology, 96(1150), Article 20230211.

5.Boehm,K.M. et al.(2022)‘Harnessing Multimodal Data Integration to Advance Precision Oncology’, Nature Reviews Cancer, 22(2), pp. 114–126.

6.Dr.Ohmini Krishnamurthy Rajendran (Author),AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4

7.Dr.Latha Kiran Krishna Rajendran (Author),IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7

8.Chakraborty, S. et al. (2022) ‘Multi-omics Integration in Oncology: From Data to Clinical Insights’, Cancer Cell, 40(8), pp. 805-823.

9.Dr.Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5

10.Dr.Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March

2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5

11.Dr.Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38

12.Dr.Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14

13.Dr.Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12

14.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18

15.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7

16.Dr.Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325,DOI: https://doi.org/10.46121/pspc.52.4.14

17.Dr.Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31

18.Dr.Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21

19.Dr.Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16

20.Dr.Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL Intelligence'DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33

21.Joshi,A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.

22.Huang,S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.

23.Dr.Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.

24.Dr.Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8

25.Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.

26.Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.

27.Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.

28.Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.

29.Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.

30.Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.